BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37231941)

  • 21. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 22. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
    Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
    Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial and recurrent ovarian carcinoma: a single center experience.
    Pavlov MJ; Ceranic MS; Latincic SM; Sabljak PV; Kecmanovic DM; Sugarbaker PH
    Int J Hyperthermia; 2018 Aug; 34(5):564-569. PubMed ID: 28877609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
    Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
    Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer.
    Brault C; Brind'Amour A; de Guerke L; Auclair MH; Sideris L; Dubé P; Soucisse M; Tremblay JF; Bernard L; Piedimonte S; Fortin S
    Curr Oncol; 2023 Dec; 30(12):10272-10282. PubMed ID: 38132382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
    Kim SI; Kim JH; Lee S; Cho H; van Driel WJ; Sonke GS; Bristow RE; Park SY; Fotopoulou C; Lim MC
    Gynecol Oncol; 2022 Dec; 167(3):547-556. PubMed ID: 36273925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
    Gadducci A; Cosio S; Lippolis PV
    Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study.
    Ceresoli M; Verrengia A; Montori G; Busci L; Coccolini F; Ansaloni L; Frigerio L
    J Gynecol Oncol; 2018 May; 29(3):e53. PubMed ID: 29533028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
    Praiss AM; Zhou Q; Iasonos A; Moukarzel L; Dessources K; Soldan K; Su K; Sonoda Y; Roche KL; Gardner GJ; Troso-Sandoval T; Tew WP; Grisham RN; Chi DS; O'Cearbhaill RE; Zivanovic O
    Gynecol Oncol; 2023 Apr; 171():23-30. PubMed ID: 36804618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
    Gelissen JH; Adjei NN; McNamara B; Mutlu L; Harold JA; Clark M; Altwerger G; Dottino PR; Huang GS; Santin AD; Azodi M; Ratner E; Schwartz PE; Andikyan V
    Ann Surg Oncol; 2023 Sep; 30(9):5597-5609. PubMed ID: 37358686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mininvasive Cytoreduction Surgery plus HIPEC for Epithelial Ovarian Cancer: A Systematic Review.
    Ronsini C; Pasanisi F; Greco P; Cobellis L; De Franciscis P; Cianci S
    Medicina (Kaunas); 2023 Feb; 59(3):. PubMed ID: 36984422
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
    Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
    Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
    Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
    Lim PQ; Han IH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
    Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
    Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
    Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
    Zivanovic O; Chi DS; Zhou Q; Iasonos A; Konner JA; Makker V; Grisham RN; Brown AK; Nerenstone S; Diaz JP; Schroeder ED; Langstraat CL; Paroder V; Lakhman Y; Soldan K; Su K; Gardner GJ; Andikyan V; Guo J; Jewell EL; Long Roche K; Troso-Sandoval T; Lichtman SM; Moukarzel LA; Dessources K; Abu-Rustum NR; Aghajanian C; Tew WP; Beumer J; Sonoda Y; O'Cearbhaill RE
    J Clin Oncol; 2021 Aug; 39(23):2594-2604. PubMed ID: 34019431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
    de Bree E; Michelakis D
    Expert Opin Pharmacother; 2020 Aug; 21(12):1479-1492. PubMed ID: 32486865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: a retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer.
    Marocco F; Vaira M; Milani A; Genta S; Maggiorotto F; Magistris A; Cinquegrana A; Robella M; De Simone M; Aglietta M; Ponzone R; Valabrega G
    Eur J Gynaecol Oncol; 2016; 37(5):638-643. PubMed ID: 29787001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study.
    Manzanedo I; Pereira F; Serrano Á; Pérez-Viejo E; Martínez-Torres B; Carrión L; Calzas J
    Clin Transl Oncol; 2019 Oct; 21(10):1357-1363. PubMed ID: 30788835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.